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Abstract 
 
This study was carried out at the University of Khartoum, faculty of 
Veterinary Medicine, Department of Biochemistry. Samples were collected 
from patients visiting the Radiation and Isotopes Center, Khartoum 
(RICK), Radio- immunoassay laboratory. This work was carried out to 
estimate the effects of subclinical thyroid disorders on important blood 
lipids values. 
The study included 120 participants, divided into three equal groups: 
subclinical hypothyroidism, subclinical hyperthyroidism, and control. 
There were obvious differences in serum levels of total cholesterol, low 
density lipoproteins- cholesterol (LDL-C), and triglycerides (TG) among 
the different groups. 
Among subjects with subclinical hypothyroidism, there was a 
significant increase (p < 0.001) in the levels of total cholesterol, when 
compared with the control. The LDL-C levels were also found to be high 
in the subclinical hypothyroidism group (p < 0.03). In contrast, the 
subclinical hyperthyroidism group showed normal values for both total 
cholesterol and LDL-C. TG levels were found to be significantly higher 
among the subclinical hypothyroid (p < 0.01) and subclinical hyperthyroid 
(p < 0.01) subjects than the controls, while no differences in the levels of 
HDL-C among the three different groups were observed. 
According to the obtained results, subclinical hypothyroidism can 
significantly increase the levels of most serum lipids including total 
cholesterol, LDL-C, and TG. However, subclinical hyperthyroidism does 
not appear to have such effect except for the TG levels. 
 
 
  
  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
  
ﺔ و أﺟﺮﻳѧﺖ اﻟﺪراﺳѧ.ﺗﻤѧﺖ هѧﺬ اﻟﺪراﺳѧﺔ ﻓѧﻲ ﻗѧﺴﻢ اﻟﻜﻴﻤﻴѧﺎء اﻟﺤﻴﻮﻳѧﺔ ﺑﻜﻠﻴѧﺔ اﻟﺒﻴﻄѧﺮة، ﺟﺎﻣﻌѧﺔ اﻟﺨﺮﻃѧﻮم
، (snoitcnufsyd lacinilcbus)ﻟﻤﻌﺮﻓﺔ أﺛﺮ اﻟﻌﻴﻮب ﺗﺤﺖ اﻟﺴﺮﻳﺮﻳﺔ ﻓﻲ إﻓѧﺮاز هﺮﻣﻮﻧѧﺎت اﻟﻐѧﺪة اﻟﺪرﻗﻴѧﺔ 
  .، ﻋﻠﻲ ﻣﺴﺘﻮى ﺑﻌﺾ اﻟﺪهﻮن ﻓﻲ اﻟﺪم(4T ,3T)اﻟﺜﻴﺮوآﺴﻴﻦ واﻟﺜﻴﺮوﻧﻴﻦ ﺛﻼﺛﻲ اﻟﻴﻮد 
 ﺗﻢ ﺟﻤﻊ اﻟﻌﻴﻨﺎت ﻣﻦ اﻟﻤﺮﺿﻲ اﻟﺬﻳﻦ زاروا ﻣﻌﻤﻞ ﻗﻴﺎس اﻟﻬﺮﻣﻮﻧﺎت ﺑﻤﺮآﺰ اﻟﻄﺐ اﻟﻨﻮوي واﻟﻌѧﻼج 
 ﻓѧﺮد ﻣѧﻦ اﻹﻧѧﺎث، ﺗѧﻢ ﺗﻘѧﺴﻴﻤﻬﻢ ﺣѧﺴﺐ اﻟﺤﺎﻟѧﺔ اﻟﻤﺮﺿѧﻴﺔ 021أﺟﺮﻳﺖ اﻟﺪراﺳﺔ ﻋﻠﻲ ﻋﺪد . KCIR()ﺔ ﺑﺎﻷﺷﻌ
ﻣﺠﻤﻮﻋﺔ ﺗﻌﺎﻧﻲ ﻣﻦ ﻗﺼﻮر ﺗﺤﺖ ﺳѧﺮﻳﺮي ﻓѧﻲ إﻓѧﺮاز هﺮﻣﻮﻧѧﺎت اﻟﻐѧﺪة : إﻟﻰ ﺛﻼث ﻣﺠﻤﻮﻋﺎت ﻣﺘﺴﺎوﻳﺔ اﻟﻌﺪد 
، ﻣﺠﻮﻋѧѧﺔ ﺗﻌѧѧﺎﻧﻲ ﻣѧѧﻦ زﻳѧѧﺎدة ﺗﺤѧѧﺖ ﺳѧѧﺮﻳﺮﻳﺔ ﻓѧѧﻲ إﻓѧѧﺮاز  msidioryhtopyh( lacinilcbus)اﻟﺪرﻗﻴѧѧﺔ 
  (. slortnoc)، وﻣﺠﻤﻮﻋﺔ ﺗﺤﻜﻴﻤﻴﺔ msidioryhtopyh lacinilcbus()ﻟﻐﺪة اﻟﺪرﻗﻴﺔ هﺮﻣﻮﻧﺎت ا
أوﺿѧѧﺤﺖ اﻟﺪراﺳѧѧﺔ أن هﻨﺎﻟѧѧﻚ ﻓﺮوﻗѧѧﺎت واﺿѧѧﺤﺔ ﺑѧѧﻴﻦ اﻟﻤﺠﻤﻮﻋѧѧﺎت اﻟѧѧﺜﻼث ﻋﻨѧѧﺪ ﻗﻴѧѧﺎس ﻣѧѧﺴﺘﻮى 
  :ﻓﻲ اﻟﺪم( C -LDL)واﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ ( sedirecylgirT)اﻟﻜﻮﻟﻴﺴﺘﻴﺮول واﻟﺠﻠﺴﺮﻳﺪات اﻟﺜﻼﺛﻴﺔ 
ﻗﺼﻮر ﺗﺤﺖ ﺳﺮﻳﺮي ﻓﻲ إﻓﺮاز هﺮﻣﻮﻧﺎت اﻟﻐѧﺪة اﻟﺪرﻗﻴѧﺔ، آѧﺎن ﻣѧﺴﺘﻮى ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﻲ ﺗﻌﺎﻧﻲ ﻣﻦ   
 < P)اﻟﻜﻮﻟﻴѧﺴﺘﻴﺮول ﻓѧﻲ اﻟѧﺪم ﻋﺎﻟﻴѧًﺎ ﺟѧﺪًا ﻣﻘﺎرﻧѧﺔ ﻣѧﻊ اﻟﻤﺠﻤﻮﻋѧﺔ اﻟﺘﺤﻜﻴﻤﻴѧﺔ ﻣﺤﻘﻘѧًﺔ ﻓﺮوﻗѧًﺎ ﻣﻌﻨﻮﻳѧﺔ واﺿѧﺤﺔ 
  .)30.0 < P(، (C -LDL)وآﺬﻟﻚ اﻟﺤﺎل ﺑﺎﻟﻨﺴﺒﺔ ﻟﻤﺴﺘﻮى اﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ (. 100.0
 ﻣﻦ زﻳﺎدة ﺗﺤﺖ ﺳﺮﻳﺮﻳﺔ ﻓﻲ إﻓﺮاز هﺮﻣﻮﻧﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ، ﻓﺈﻧﻬﺎ ﻟѧﻢ أﻣﺎ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﺠﻤﻮﻋﺔ اﻟﺘﻲ ﺗﻌﺎﻧﻲ   
  (.C -LDL)ﺗﺴﺠﻞ أي ﻓﺮوق ﻣﻌﻨﻮﻳﺔ ﻓﻲ ﻣﺴﺘﻮﻳﺎت اﻟﻜﻮﻟﻴﺴﺘﻴﺮول و اﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ 
ﻣѧﺴﺘﻮﻳﺎت ﻋﺎﻟﻴѧﺔ ﺑѧﻴﻦ أﻓѧﺮاد اﻟﻤﺠﻤѧﻮﻋﺘﻴﻦ ( sedirecylgirT)ﺳﺠﻠﺖ ﻣѧﺴﺘﻮﻳﺎت اﻟﺠﻠѧﺴﺮﻳﺪات اﻟﺜﻼﺛﻴѧﺔ   
 ، آﺎﻧѧﺖ اﻟﻨﺘѧﺎﺋﺞ C -LDH()أﻣﺎ ﻋﻨﺪ ﻗﻴﺎس اﻟﺒѧﺮوﺗﻴﻦ اﻟѧﺪهﻨﻲ . ﻴﺔﻋﻠﻰ اﻟﺴﻮاء ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﺤﻜﻴﻤ
  .ﻣﺘﺸﺎﺑﻬﺔ ﻓﻲ آﻞ اﻟﻤﺠﻤﻮﻋﺎت اﻟﺜﻼث وﻟﻢ ﺗﺴﺠﻞ ﻓﺮوﻗﺎت واﺿﺤﺔ
إﺳﺘﻨﺎدًا ﻋﻠﻲ اﻟﻨﺘﺎﺋﺞ اﻟﻤﺘﺤﺼﻠﺔ ﻣﻦ اﻟﺪراﺳﺔ، ﻳﺘﻀﺢ أن اﻟﻘﺼﻮر ﺗﺤﺖ اﻟѧﺴﺮﻳﺮي ﻓѧﻲ إﻓѧﺮاز هﺮﻣﻮﻧѧﺎت   
ﻲ اﻟѧѧﺪم واﻟﺘѧѧﻲ ﺷѧѧﻤﻞ اﻟﻜﻮﻟﻴѧѧﺴﺘﻴﺮول، اﻟﻐѧѧﺪة اﻟﺪرﻗﻴѧѧﺔ ﻟѧѧﻪ ﺗѧѧﺄﺛﻴﺮ واﺿѧѧﺢ ﻓѧѧﻲ زﻳѧѧﺎدة ﻣѧѧﺴﺘﻮﻳﺎت ﻣﻌﻈѧѧﻢ اﻟѧѧﺪهﻮن ﻓѧѧ 
ﺑﻴﻨﻤѧﺎ اﺗѧﻀﺢ أن اﻟﺰﻳѧﺎدة ﺗﺤѧﺖ (. sedirecylgirT)، واﻟﺠﻠѧﺴﺮﻳﺪات اﻟﺜﻼﺛﻴѧﺔ C -LDL( )اﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ 
اﻟѧѧﺴﺮﻳﺮﻳﺔ ﻓѧѧﻲ إﻓѧѧﺮاز هﺮﻣﻮﻧѧѧﺎت اﻟﻐѧѧﺪة اﻟﺪرﻗﻴѧѧﺔ ﻳﻤﻜѧѧﻦ أن  ﻳﻘﺘѧѧﺼﺮ ﺗﺄﺛﻴﺮهѧѧﺎ ﻓﻘѧѧﻂ ﻋﻠѧѧﻰ ﻣﺴﺘﻮىﺎﻟﺠﻠѧѧﺴﺮﻳﺪات 
  (.sedirecylgirT)اﻟﺜﻼﺛﻴﺔ 
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Introduction 
 
Sudan was first reported as an endemic goiter area by Woodman in 
1952, when different areas described in southern Sudan (Eltom et al. 
1984). Kambal, (1967) completed an extensive survey comprising 17470 
people in Dar Fur province (Western Sudan) and found that 57% were 
goiterous. In Khartoum 12.6% of 5566 subjects were found to have 
goiter. Eltom et al. (1984) showed that the incidence of endemic goiter 
among school children in Dar Fur was 85 %. Endemicity also started to 
spread and a new focus was reported by Eltom et al. in central Sudan 
(Kosti) .It is estimated that 14 million of the 25 million inhabitants of 
Sudan are at risk of having iodine deficiency and consequently thyroid 
problem. Irrespective of this high incidence of thyroid disease, the 
normal range for thyroid hormones was not established for the Sudanese 
population. 
The thyroid gland maintains the level of metabolism in the tissues 
that is optimum for their normal function. Thyroid hormones are well 
known to stimulate the oxygen consumption of most of the cells in the 
body, helps to regulate lipid and carbohydrates metabolism, modulation 
of gonadotropin secretion by the pituitary and maintenance of 
proliferative cell growth and maturation in hair. In addition, thyroid 
hormones stimulate both sodium pump and glycolytic pathway leading to 
calorigenesis and oxidative phosphoralytion in tissues such as liver, 
kidney, and muscle (Ganong, 1997).  
Physiological concentrations exert both anabolic and catabolic 
effects promoting the normal metabolic turn-over, but higher 
  
concentrations exert catabolic responses. Decreased thyroid hormones 
level (hypothyroidism) leads to poor resistance to cold, mental and 
physical slowing, muscle weakness, cramps and stiffness. In children, 
there is mental retardation, deaf mutism and other neurological 
abnormalities (cretinism). Excess thyroid hormones secretion 
(hyperthyroidism) leads to body wasting, nervousness, tachycardia, 
tremor, muscle weakness (thyrotoxic myopathy) and excess heat 
production (Ganong, 1997). 
 
Subclinical thyroid dysfunction is a common clinical problem for 
which there are many controversial issues regarding screening, 
evaluation, and management. Subclinical hyperthyroidism and 
hypothyroidism have subtle clinical manifestations at most, and the 
importance of timely diagnosis and treatment continue to be contentious 
subjects of research studies, position papers, and editorials. Both 
Subclinical hyperthyroidism and subclinical hypothyroidism have many 
clinical implications that can be seriously harmful if not treated. These 
include: progression to overt hypo and hyperthyroidism, cardiovascular 
diseases, atria fibrillation, osteoporosis and bone fracture (Helfand, 
2004). 
Previous studies conducted on subclinical thyroid dysfunctions 
in Sudan, are lacking. The aim of this study was to estimate the 
relation of Subclinical hypo and hyperthyroidism to serum lipids, and 
to compare the findings with those reported in the literature. 
According to Tunbridge et al. (1977) and Hak et al. (2000), 
subclinical disorders are found to be common and twice as often in 
  
women as in men, so only women were chosen to participate in the 
present study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter One 
Literature Review  
 
1.1. The Thyroid gland 
The thyroid gland was first described by Galen and was named 
"glandluae thyroidaeae" by Wharton in (1656). While Harrington 
(1935) reviewed the many older opinion concerning the function of 
this gland (Hardman and Limbird, 2001). It is a flat –appearing 
bilobed, pink structure, lying on either side of trachea lateral and 
inferior to the thyroid cartilage. The thyroid is the largest endocrine 
gland in man weighing about 20 grams in adults. The thyroid is so 
called because of its shield-shaped configuration (Merck, 2005). 
The principal hormones of the thyroid gland are iodine 
containing amino acids derivatives of primary 3,5,3́,5 ́-L-
tetraiodothyronine (thyroxine T4) and a lesser quantity of 3,5,3 ́-L-
triioodothyronine (T3). In addition, the parafollicular cells of human 
thyroid gland secrete calcitonin, which is important in calcium 
homeostasis (Merck, 2005). 
 
1.2. Thyroid hormones synthesis 
The major steps in the synthesis, storage, release, and 
interconversion of thyroid hormones are the following: (1) the uptake 
of iodide ion by the gland; (2) the oxidation of iodide and iodination 
of tyrosyl residues in thyroglobulin; (3) Coupling of iodotyrosine 
residues within thyroglobulin to generate the iodothyronines; (4) the 
  
proteolysis of thyroglobulin, with release of free iodothyronines and 
iodotyrosines; (5) the conversion of T4 to T3 in peripheral tissues as 
well as in the thyroid, with conversion and reuse of librated iodide 
(Hardman and Limbird, 2001). 
 
1.3. Iodide transport (the iodide trap) 
Thyroid hormones are unique in that they require the trace 
element iodine for biologic activity. A complex mechanism has 
evolved to acquire and retain this crucial element and to convert it into 
a form suitable for incorporation into organic compound. The thyroid 
is able to concentrate I⎯ against a strong electrochemical gradient 
which is an energy-dependant process and is linked to the ATPase-
dependant Na+/K+ pump which in turn controlled primarily by TSH 
(Murray et a.l, 2003). I⎯ is transported across the basement membrane 
of the thyroid cell by an intrinsic membrane molecule called the Na+/I⎯ 
symporter (NIS). The NIS derives its energy from Na+/K+, ATPase, 
which derives the transport process. This active transport system 
allows the human thyroid gland to maintain a concentration of free 
iodide 30-40 times that in plasma (Williams, 2001). The transport 
mechanism is frequently called the "iodide- trapping mechanism" or 
"iodide pump". The pump is an example of secondary active transport 
(Ganong, 1997).  A very small amount of iodide enters the thyroid by 
diffusion. Also any intracellular I⎯ that is not incorporated into 
monoiodotyrosine (MIT) or diiodtyrosine (DIT) is free to leave by this 
mechanism (Murray et al., 2003). 
Two thirds of the absorbed iodine is excreted in the urine within 
2 to 3 days after ingestion, and may also be lost in the faeces, sweat 
  
and milk. Most of this iodine comes from the breakdown of thyroid 
hormones (Williams, 2001). 
 
1.4. Thyroglobulin   
Thyroglobulin is a large glycoprotein molecule containing 5496 
amino acids. It contains about 140 tyrosyl residues and about 10% 
carbohydrate. Thyroglobulin is unique among body proteins in its 
content of iodinated amino acids (Taurgo, 1978). The greatest part of 
iodine in the thyroid glands of animals on adequate iodine intake 
exists in the form of thyroglobulin. The iodotyrosines "T4 and T3 
precursor" form the most abundant iodinated amino acid components 
of thyroglobulin. . 
 
1.5. Proteolysis of thyroglobulin and thyroid hormone secretion 
 At the cell-colloid interface, colloid is engulfed into a colloid 
vesicle by a process of macropinocytosis or micropinocytosis and is 
absorbed into the thyroid cell. The lysosomes then fuse with the 
colloid vesicle and hydrolysis of thyroglobulin occurs, releasing T4, 
T3, DIT, MIT, peptide fragments, and amino acids. T3 and T4 are 
released into the circulation, while DIT and MIT are deiodinated by 
intrathyrodial deiodinase and the I⎯ is conserved and mostly reutilized 
for hormone synthesis although a small amount leaks out of the 
thyroid into the body pool. A small amount of unhydrolysed 
thyroglobulin is also released from the thyroid cell (Williams, 2001).   
 
 
  
1.6. Transport of thyroid hormones 
Thyroid hormones are transported in serum bound to carrier 
proteins. There are three major thyroid hormones transport protein: 
thyroxine-binding globulin (TBG); thyroxine-binding prealbumin 
(TBPA); and albumin. T4 and T3 have a high affinity for TBPA which 
allow it to carry about 70% of the circulating thyroid hormones. When 
fully saturated, TBG can carry about 20 µg of T4/dl. TBG binds about 
10 % of the circulating T4. Its affinity for T3 is about 10 fold lower 
than for T4, so that it mostly carries T4. Albumin has one strong 
binding site for T4 and T3 and several weaker ones. Because of its 
high concentration in serum, albumin carries about 15% of circulating 
T4 and T3 (Williams, 2001). 
 
1.7. Metabolism of thyroid hormones 
 The daily secretion of the normal thyroid gland is about 100 
nmol of T4, about 5 nmol of T3, and less than 5 nmol of metabolically 
inactive reverseT3 (rT3) (Williams, 2001).  
 T4 and T3 are deiodinated mainly in the liver, the kidney, and 
many other tissues. Two different enzymes are involved, 5 ́-deiodinase 
catalyzing the formation of T3, which is three to eight times more 
potent than T4, and 5-diodinase catalyzing the formation of r-T3, 
which is metabolically inert. T3 and r-T3 are then converted to various 
diiodothyronines (Ganong, 1997). Monodeiodination of the outer ring 
of thyroxine is a "step up" process; increasing the metabolic activity of 
the resultant compound, while monodeiodination of the inner ring is a 
"step down" or inactivation process. Further deiodination of the 
molecule abolishes normal activity.  
  
Most peripheral target tissues utilize T3 that is derived from the 
circulating hormone. Notable exceptions are the brain and pituitary, 
for which local generation of T3 is a major source for the intracellular 
hormone (Hardman and Limbird, 2001).                                                
 
1.8. Thyroid stimulating hormone 
Thyroid stimulating hormone (TSH), or thyrotropin, is a 
glycoprotein synthesized and secreted by the thyrotrophs of the 
anterior pituitary gland. TSH is a primary factor controlling thyroid 
cell growth and thyroid hormones synthesis and secretion. It achieves 
this effect by binding to specific TSH receptor (TSH-R) on the thyroid 
cell membrane and activating both the G protein-adenyl cyclase-
cAMP and the phospholipase C signaling systems (Williams, 2001).  
The serum level of TSH is about 0.4-4.0 mU/L; it is increased 
in hypothyroidism and decreased in hyperthyroidism. TSH secretion is 
controlled by a negative feedback mechanism modulated by the 
circulating level of free T4 and free T3 and by conversion of T4 to T3 in 
the pituitary thyrotropic cells. Increased levels of free thyroid 
hormones (T4 and T3) inhibit TSH secretion from the pituitary, 
whereas decreased levels of T4 and T3 result in an increased TSH 
release from the pituitary. TSH secretion is also influenced by 
thyrotropin-releasing hormone (TRH), a 3-amino acid peptide 
synthesized in the hypothalamus. The precise regulation of TRH 
synthesis and release is not clear, although thyroid hormones do play a 
role (Merck, 2005). 
Changes in thyroid cell morphology and size are found to be 
one of the most ovious effects of TSH in the thyrocytes. Also TSH 
stimulates all phases of iodide metabolism, from increased iodide 
  
uptake and transport to increased iodination of thyroglobuline and 
increased secretion of thyroid hormones. Other effects of TSH include 
increase in mRNA for thyroglobulin and thyroperoxidase, with 
increase in incorporation of I⎯ into MIT, DIT, T4, and T3. TSH has 
still other effects on the thyroid gland, including stimulation of 
glucose uptake, oxygen consumption, CO2 production, and increase in 
glucose oxidation. Also there is accelerated turn over of phospholipids 
and stimulation of synthesis of purine and pyrmidine precursors, with 
increased synthesis of DNA and RNA (Williams, 2001). 
 
1.9. Effects of thyroid hormones 
It is likely that all cells in the body are targets for thyroid 
hormones. While not strictly necessary for life, thyroid hormones have 
profound effects on many "big time" physiologic processes, such as 
development, growth and metabolism. Some of the widespread effects 
of thyroid hormones in the body are secondary to stimulation of O2 
consumption (calorigenic action), although the hormones also affect 
and regulate lipid metabolism, and increase the absorption of 
carbohydrates from the intestine (Hardman and Limbird, 2001). 
 
1.9.1. Calorigenic action 
A characteristic response of homoeothermic animals to thyroid 
hormone is increased oxygen consumption of almost all metabolically 
active tissues. The exceptions are the brain, tests, uterus, lymph nodes, 
spleen, and anterior pituitary. Indeed 30% to 40% of the thyroid 
hormone-dependant increase in oxygen consumption can be attributed 
to stimulation of cardiac contractility. At one time it was erroneously 
  
believed that thyroid hormone uncoupled mitochondria oxidative 
phosphorylation. Thyroid hormones-dependant lipogenesis may 
constitute a quantitavely important energy sink. Further, thyroid 
hormones induce expression of several lipogenic enzymes.  
Although the entire picture is not clear, there appears to be an 
integrated thyroid hormone response program for regulating the set-
point of energy expandture of maintaining the metabolic machinery 
necessary to sustain it (Hardman and Limbird, 2001). 
 
1.9.2. Effects on growth 
Thyroid hormones are essential for normal growth and skeletal 
metabolism. In hypothyroid children, bone growth is slowed and 
epiphyseal closure delayed. Not surprisingly, the growth-promoting 
effect of thyroid hormones is intimately intertwined with that of 
growth hormone. In the absence of thyroid hormones, growth 
hormone secretion is also depressed and thyroid hormones potentiate 
the effect of growth hormone on tissues (Ganong, 1997).  
1.9.3. Effects on lipids metabolism 
Alterations of the lipid profile are well known phenomena in 
thyroid dysfunction. Thyroid hormones regulate lipid metabolism 
through various mechanisms. Increased thyroid hormone levels stimulate 
fat mobilization, leading to increased concentrations of fatty acids in 
plasma. They also enhance oxidation of fatty acids in many tissues. 
Finally, plasma concentrations of cholesterol and triglycerides are 
inversely correlated with thyroid hormone levels (Spandrio et al., 1993).   
  
It has been known for over fifty years that an increase in thyroid 
activity reduces the level of cholesterol in blood whereas a decrease in 
thyroid activity increases it. The blood cholesterol level represents the 
balance between ingestion and formation in one hand and excretion and 
utilization on the other. The action of the thyroid gland on cholesterol 
metabolism is complex. It stimulates the formation of cholesterol by the 
liver, but has greater effect on increasing the excretion of cholesterol in 
the bile, and increasing the entry of cholesterol into cells. The net result 
is that the blood level falls. Also it was clearly approved that the decrease 
in plasma cholesterol concentration is due to increased formation of LDL 
receptors in the liver, resulting in increased hepatic removal of 
cholesterol from the circulation (Ganong, 1997). 
In hypothyroidism, the number of LDL-receptors is decreased 
and results in increased serum total cholesterol and LDL-cholesterol 
(Chiat, et al., 1979; Thompson, et al. 1987). However, Gross et al., 
(1987) reported that hyper-cholesterolaemia associated with 
hypothyroidism is due partly to increased HDL-cholesterol 
concentration Also the hepatic excretion of cholesterol and its 
conversion to bile acids are decreased and improve by thyroxine 
administration.  
A study carried out by Duntas and Leonidas, (2002) showed 
that hyperthyroidism exhibits an enhanced excretion of cholesterol 
and increased turn over of LDL resulting in a decreased total and 
LDL-cholesterol, whereas HDL is decreased or not affected. Also, the 
composition and the transport of lipoproteins are seriously disturbed in 
thyroid diseases. Rassoul, et al., (1988) postulated that clinical 
manifestation of hypothyroidism lead to changes of plasma 
  
lipoproteins, which are characterized by elevated LDL-cholesterol, an 
increase of the ratio of LDL-cholesterol/ HDL-cholesterol. On the 
contrary patients with hyperthyroidism showed low lipoproteins 
levels. 
 Triglycerides output is decreased by thyroid hormones, while 
hypothyroidism is often accompanied by hypertriglycerdaemia as 
reported by Muller and Seiz, (1984) and Gomo and Ascot, (1994). 
Also it was found that in hypothyroidism; the catabolism of VLDL-
cholesterol by lipoprotein lipase is also impaired resulting in an 
increased serum TG (Abrams, et al 1981). The degradation of TG 
contributes to the enhanced thermogenesis in hyperthyroid patients 
(Muller and Seiz, 1984). 
Dullaart et al (1990) studied the activity of cholesteryl-ester 
transfer protein (CETP). He found that the thyroid hormones are 
involved in the regulation of (CETP) activity and that may play a role 
in the alterations in HDL-cholesterol lipids observed in 
hypothyroidism. Also Duntas and Leonidas, (2002) reported that, 
there is a marked increase in HDL levels in hyperthyroid patients due 
to increased activity of (CETP) and hepatic lipase (HL) which are 
regulated by thyroid hormones. He suggested that the low activity of 
(CETP) and more specifically of (HL), results in reduced transport of 
cholesteryl esters from HDL to VLDL and IDL and reduces transport 
of HDL2 to HDL3.  
From all reported literature, it is clear that hypothyroidism and 
hyperthyroidism have opposite effects on plasma lipids and 
apolipoproteins.  
 
  
 
1.9.4. Effects on carbohydrate metabolism 
Thyroid hormones increase the rate of absorption of 
carbohydrate from the gastrointestinal tract, an action that is probably 
independent of their calorigenic action (Ganong, 1997).  
Thyroid hormones stimulate almost all aspects of carbohydrate 
metabolism, including enhancement of insulin-dependent entry of 
glucose into cells and increased gluconeogenesis and glycogenolysis 
to generate free glucose. Several studies have shown that thyroid 
hormone is associated with glucose intolerance resulting from 
decreased glucose stimulated insulin secretion. This defect in insulin 
secretion is believed to result from an increase in the rate of apoptosis 
(programmed cell death) of pancreatic beta cells as a direct effect of 
thyroid hormone excess. This process is reversible, since when thyroid 
hormone is withdrawn the rate of beta cell replication increases until 
homeostasis returns (Jorns, et al, 2002). 
 
1.9.5. Effects on protein metabolism 
Thyroid hormones increase protein synthesis in virtually every 
body tissue (T3 within the cell binds to discrete nuclear receptors and 
influences the formation of mRNA) Both protein synthesis and 
degradation of protein are increased in most patients with 
thyrotoxicosis. The increased degradation of protein comes to a 
greater extent than the former, as a result there is a net degradation of 
tissue protein. This is an evident in negative nitrogen balance, loss of 
weight, muscle wasting, weakness, and mild hypoalbuminemia 
(Greenspan and Gardner, 2004).  
  
 
1.9.6. Effects on vitamin metabolism 
 Thyroid hormones increase the demand for coenzymes and the 
vitamins from which they are derived. In hyperthyroidism, the 
requirement for water-soluble vitamins, such as thiamine, riboflavin, 
vitamin B12, and vitamin C, is increased and their tissue 
concentrations are reduced. The conversion of some water-soluble 
vitamins to the coenzymes form may be impaired, possibly as a result 
of defective energy transfer. On the other hand, the synthesis of some 
coenzymes from vitamins requires thyroid hormones. The metabolism 
of fat-soluble vitamins is also influenced by thyroid hormones. They 
are required for the synthesis of vitamin A from carotene and for the 
conversion of vitamin A to retinal. Moreover, it was found that 
vitamins D and E appear to be deficient in hyperthyroid animals 
(Williams, 2001). 
 
1.9.7. Effects on heart and skeletal muscle 
 Thyroid hormones increase the number and affinity of             
B-adrenergic receptors in the heart and consequently increase its 
sensitivity to the inotropic and chronotropic effects of 
chatecholeamines. They also affect the type of myosin found in 
cardiac muscle and consequently this affect ATPase activity. 
 Muscle weakness occurs in most patients with hyperthyroidism. 
This may be due in part to increased protein catabolism. Thyroid 
hormones affect the expression of the myosin heavy chain (MHC) 
gene in skeletal as well as cardiac muscle. However, the effects 
produced are complex and their relation to myopathy is not 
  
established. Hypothyroidism is also associated with muscle weakness, 
cramps, and stiffness (Ganong, 1997).  
 
1.9.8. Effects on nervous system 
 In hypothyroidism, mentation is slow and the cerebral spinal 
fluid (CSF) protein level elevated. Thyroid hormones reverse the 
change and large doses cause rapid mentation, irritability, and 
restlessness. 
 Some of the effects of thyroid hormones on the brain are 
probably secondary to increased responsiveness to catecholamines, 
with consequent increased activation of the reticular activating system. 
In addition, thyroid hormones have marked effects on brain 
development; the parts of the CNS most affected are the cerebral 
cortex and the basal ganglia. Consequently, thyroid hormone 
deficiency during development causes mental retardation, motor 
rigidity, and deaf-mutism. Thyroid hormones also exert effects on the 
peripheral nervous system. The reaction time of stretch reflexes is 
shortened in hyperthyroidism and prolonged in hypothyroidism 
(Ganong, 1997). 
 
1.10. Thyroid dysfunctions 
The most thyroid disorders include: euthyroid goiter, euthyroid 
sick syndrome, hyperthyroidism, hypothyroidism, thyroiditis, 
subclinical hypothyroidism, subclinical hyperthyroidism, and thyroid 
cancers. Discussion of the synthesis and physiology of thyroid 
hormones and of the laboratory testing of thyroid function are 
  
prerequisites to a thorough understanding of these disorders (Merck, 
2005). 
1.10.1. Subclinical hypothyroidism 
Subclinical hypothyroidism is a term used for a condition in 
which there are small elevations in thyroid stimulating hormone (TSH) , 
yet, normal circulating levels of thyroid hormones (William and 
William, 2004). This biochemical state has been given a variety of other 
names, including mild thyroid failure, as well as compensated, early, 
late, mild, minimally symptomatic, and pre-clinical hypothyroidism. 
(Arem and Escalante, 1996). The term "subclinical" may not be strictly 
correct, since some of patients may have clinical symptoms, but no 
better terms are more appropriate (Adlen, 1998). 
 The world prevalence of subclinical hypothyroidism ranges from 
1-10 percent; the highest age-and sex- specific rates are in women older 
than 60 years of age approaching 20 percent in some reports. 
(Tunbridge et al., 1977, Canaris et al., 2002).In the Whickham survey, 
TSH levels above 6 mIU/L were approximately three times more 
common in females than males and occurred more frequently in 
females over 45 years of age. (Tunbridge et al., 1977). 
 
1.10.1.1. Causes 
Subclinical hypothyroidism is caused by the same disorders of 
the thyroid gland as those that cause overt hypothyroidism such as 
chronic autoimmune thyroiditis, treated Graves' disease, congenital, 
hypopituitarism, iodine deficiency, radioactive therapy & antithyroid 
drugs. Chief among these is chronic autoimmune thyroiditis 
  
(Hashimoto's disease), which is commonly associated with increased 
titers of antithyroid antibodies (Adlen, 1998). Medications such as 
lithium and aminodarone, sulfonyl ureas and ethioamide can interfere 
with thyroid hormone production or release and secondary result in a 
slight elevation of (TSH) (Kek et al., 2003). 
1.10.1.2. Clinical implications  
 Clinical manifestations of subclinical hypothyroidism include 
abnormal lipid metabolism, cardiac dysfunction, and several cross-
sectional studies have suggested that it confers an elevated risk of 
atherosclerosis and coronary heart disease. However, neither of these 
associations has been confirmed by others (Imaizumi et al., 2004). 
1.10.1.2.1. Serum Lipids 
 The relationship between mild thyroid failure and reversible 
elevation in serum lipid levels has been widely investigated, but, the 
findings remain controversial. 
 In patients with full-blown hypothyroidism, serum levels of 
triglycerides (TG), total cholesterol and low-density lipoproteins 
(LDL) cholesterol are elevated. In patients with subclinical 
hypothyroidism, not surprisingly, the same changes are present but are 
less marked and less consistent. This pattern of lipid abnormalities, of 
course, is important because it is a risk factor for atherosclerotic 
cardiovascular disease (Adlen, 1998). 
 Several cross-sectional studies have demonstrated that serum 
levels of total cholesterol and LDL cholesterol are higher in patients 
with subclinical hypothyroidism than in euthyroid controls (Cooper, 
2001). It is believed that is resulted from impaired metabolism due to 
  
a decreased thyroid function (Langer et al., 2003). In other similar 
studies, however, the observed differences between euthyroid and 
mild hypothyroid individuals have not been significant (Geul et al., 
1993, Prale et al., 1992). Several authors showed a significant 
reduction of such lipid level after restoration of euthyroid state with 
thyroxine substitution treatment (Langer et al., 2003). 
1.10.1.2.2. Cardiac effects 
Cardiac changes are evident in subclinical hypothyroidism. 
These include impairment of left ventricular diastolic function at rest 
(affecting the relaxation of the ventricle and hence ventricular filling), 
reduced LV systolic function, prolongation of pre-ejection time, and 
lastly intrinsic myocardial contractility (Kek et al, 2003). It has been 
demonstrated in the Rotterdam study that subclinical hypothyroidism 
is a strong indicator risk for atherosclerosis and myocardial infarction 
(Hak et al., 2002). Impairment of endothelium-dependent 
vasodilatation, a harbinger of atherosclerosis, has been detected in 
patients with subclinical hypothyroidism (Lekais et al., 1997). In view 
of clear structural and biological cardiovascular risks associated with 
the presence of subclinical hypothyroidism, treatment of this condition 
would be expected to provide protection against the development of 
cardiovascular disease, although there have been no long term 
outcome studies published to date (Kek et al., 2003). 
1.10.1.2.3. Somatic and neuromuscular effects 
 Patients with subclinical hypothyroidism can have subtle 
clinical manifestation and non-specific symptomatology such as dry 
  
skin, cold intolerance, constipation, and easy fatigability. In addition 
patients with muscular symptoms have mitochondrial oxidative 
dysfunction with significant lactate increment during exercise. 
Misiunas et al., (1995), also demonstrated the presence of subclinical 
polyneuropathy of probable axonal origin in patients with subclinical 
hypothyroidism. Subclinical hypothyroidism subjects reported 
significantly more total symptoms than euthyroid individual in the 
Colorado study (Canaris et al., 2000) and these symptoms do improve 
with L-T4 therapy. Prospective studies suggest that patients with mild 
thyroid failure have a higher prevalence of somatic symptoms, mood 
disorders, cognitive dysfunction, and atypical responses to standard 
psychiatric therapeutic interventions (Ayala et al, 2002). The lifetime 
frequency of depression is significantly higher in patients with 
subclinical hypothyroidism compared with patients with normal 
thyroid function, suggesting that subclinical hypothyroidism lowers 
the threshold for depression (Lekais et al., 1997). 
1.10.1.3. Treatment options 
 To date there is still no consensus regarding the treatment of 
subclinical hypothyroidism. Evidence seems to indicate that 
subclinical hypothyroidism represent the mildest form of thyroid 
hormone deficiency and may be associated with adverse 
consequences. Some authors have taken the approach of treating 
patients with subclinical hypothyroidism with view to overall 
symptomatic improvement, lowering effect of lipoprotein fractions 
and prevention of progression of cardiac abnormalities (Kek et al., 
2003).  
  
Treatment is similar to that recommended in patients with overt 
hypothyroidism. Levothyroxine is the agent of choice, rather than a 
preparation containing T3, since T3 has short half-life and requires 
multiple daily doses to maintain blood levels in the normal range. 
Levothyroxine, however, has a long half-life and is partially converted 
to T3 in the body, resulting in a constant physiologic blood level of 
both T4 and T3 with a single dose (Roti et al., 1993). The goal of 
therapy is to maintain TSH levels within the normal biological range 
and usually a small dose of Levothyroxine is sufficient. Special 
caution should be exercised in patients with ischemic heart disease. In 
theses cases, a more conservative approach to starting therapy is 
indicated to prevent dysrhymias, worsening angina, or even 
precipitation of myocardial infarction (Kek et al., 2003). 
1.10.2. Subclinical hyperthyroidism 
 Subclinical hyperthyroidism is defined as persistently 
suppressed serum TSH with normal thyroxine and triiodothyronine in 
patients who do not have symptoms (Kek et al., 2003). 
 While the diagnostic criteria and treatment modalities for overt 
hyperthyroidism are well known, the literature on assessment and 
treatment of patients with subclinical hyperthyroidism is markedly 
less extensive. The precise pathophysiology, natural history, risks and 
long-term outcome of subclinical hyperthyroidism are unknown. 
(Diane and Kenneth, 2002). 
 The prevalence of subclinical hyperthyroidism varies amongst 
the reports. To date, there is no definitive information about the 
incidence of subclinical hyperthyroidism in the general population. Its 
  
prevalence ranges from 0.6 to 16% depending on diagnostic criteria, 
the sensitivity of the methods used to measure serum TSH and iodine 
intake. Moreover, the reported concentrations, prevalence of 
subclinical hyperthyroidism is affected by the investigator’s definition 
of the lower limit of the normal range for TSH being 0.7% when the 
TSH cut-off point was 0.1mU/l and 2.1% with a TSH cut-off of 0.3 
mU/l (Biondi et al., 2005). Prevalence of subclinical hyperthyroidism 
was reported to be 10%in Wickham Survey (Tunbridage et al, 1977) 
and 12% in the Framingham Study (Utiger, 1994). More recently, the 
Colorado Thyroid Disease Prevalence Study involving 25,862 subjects 
showed a prevalence of 2.1% (Canaris, et al., 2000). Hollowel et al., 
(2002) reported a population representative study of 17,353 people 
aged 12 and above and found that the prevalence of subclinical 
hyperthyroidism was only 0.7%.  
1.10.2.1. Causes 
 Most patients with subclinical hyperthyroidism are ambulatory 
outpatients who are otherwise relatively healthy or have stable, 
chronic medical conditions. Abnormalities in the TSH remain for 
months or years in the absence of overt clinical symptoms (Diane and 
Kenneth, 2002). 
 The most common causes of subclinical hyperthyroidism are 
excessive thyroid hormone therapy. The causes can be endogenous as 
Graves' (early in its course) or it can be caused by thyroid conditions 
such as autonomous adenoma, multinodular goiter, or thyroiditis, or 
due to nonthyriodal conditions euthyroid sick syndrome, acute 
psychiatric disease, pituitary and hypothalamic disorders, pregnancy 
  
and drugs: thyroxine dopamine, glucocorticoids, aspirin and 
furosemide (Kek et al., 2003). In patients with toxic adenoma or 
multinodular goiter, subclinical hyperthyroidism is usually a slowly 
progressive disorder and may last several years before being 
diagnosed (Biondi et al., 2005). 
1.10.2.2. Clinical implications 
Increasingly, it is recognized that subclinical hyperthyroidism is 
not merely a biochemical abnormality dissociated from the clinical 
manifestations and squeal of thyrotoxicosis. In fact, clinical features of 
thyrotoxicosis can be identified in subclinical hyperthyroidism albeit 
of insufficient severity to cause major symptoms. The clinical 
significance of subclinical hyperthyroidism thus relates to three risk 
factors: progression to overt hyperthyroidism, cardiac effect, skeletal 
effects (Kek et al., 2003). 
 
1.10.2.2.1. Cardiac effects 
  Patients with subclinical hyperthyroidism are at increased 
risk for cardiac abnormalities. The data on cardiac effects come 
largely from studies of patients on L-T4 suppressive therapy. TSH 
secretion for a period one to nine years showed a number of 
significant cardiovascular changes: 1) increased heart rate, 2) 
increased incidence of atria arrhythmia such as atria premature beats, 
3) increased left ventricular mass, left ventricular posterior wall and 
interventricular systolic function. Also many studies proved that 
subclinical hyperthyroidism is a risk factor for the development of 
atrial fibrillation (Kek et al., 2003). 
  
1.10.2.2.2. Skeletal effects 
The issue of increased bone loss in patients with subclinical 
hyperthyroidism has also been studied, although the published reports 
are generally small studies that were not controlled, prospective, long 
term, or double blinded. Premenopausal women with subclinical 
hyperthyroidism do not appear to be at increased risk of bone loss; 
whereas two, meta analysis concluded that postmenopausal women 
with hyperthyroidism may be at increased risk of bone loss. An 
analysis of 1,250 subjects enrolled in 41 studies revealed that in 
postmenopausal women, suppressive thyroid hormone therapy was 
associated with significant bone loss in the trail similarly led to the 
conclusion that postmenopausal women had enhanced bone loss when 
taking suppressive dose of thyroid hormone (Diane and Kenneth, 
2002). 
1.10.2.2.3. Progression to overt hyperthyroidism 
Results of long-term studies suggest that subclinical 
hyperthyroidism may develop into overt disease at a rate of at least 1 
to 3 percent per year. In the Whickham Survey where 2,779 subjects 
were followed up for 20 years, subclinical hyperthyroidism subjects 
with initial suppressed but detectable TSH levels tend to return to 
normal on follow-up, while those with undetectable TSH remained 
unchanged with small risk of progression to frank hyperthyroidism 
(Vanderpump et al., 1995). The rate of progression to overt 
hypothyroidism has been estimated to be 5% per year with subjects 
with autonomous thyroid adenoma and nodular goiter (Wjersinga, 
  
1995). Therefore, the like hood of progression of subclinical 
hyperthyroidism to overt hypothyroidism is small. 
1.10.2.2.4. Other clinical features 
 With the exception of one study, subclinical hyperthyroidism is 
associated with relevant signs and symptoms of thyroid hormone 
excess, and with impaired quality of life. With different kinds of 
questionnaires formulated to investigate the psychophysical effects of 
thyroid hormone, patients with subclinical hyperthyroidism, whether 
exogenous or endogenous, were found to have a higher prevalence of 
palpitations, tremor, heat intolerance, sweating, nervousness, anxiety, 
reduced feeling of well-being, fear, hostility, and inability to 
concentrate. Noteworthy, in a retrospective study a near threefold 
increased risk of dementia and Alzheimer’s disease was found in 
patients with subclinical hyperthyroidism (Biondi et al., 2005). 
1.10.2.3. Treatment Options 
Treatment modalities in patients with subclinical 
hyperthyroidism have not been studied for long-term, and alternative 
treatment options have not been compared in controlled clinical 
studies. As has been mentioned, few data are available to guide 
clinical decision regarding the treatment of endogenous subclinical 
thyrotoxicosis. A decision regarding the treatment of subclinical 
hyperthyroidism has based on evidence-based research in problematic 
because prospective controlled studies comparing different therapies 
do not exist. Therefore, individual studied, case report, and personal 
clinical experience must serve as parameters for assessing patients 
  
with subclinical hyperthyroidism. These patients could be treated with 
either antithyroid agents, surgery, or radioactive iodine or, 
alternatively, theses patients could simply be monitored periodically 
(Burman et al., 1995) 
 The American Thyroid Association recommends that serum 
TSH concentration screening be instituted at age 35 years in both men 
and women and be repeated every five years (Burman et al., 1995), 
while the American Association of Clinical Endocrinology had 
recommended treatment of patients with symptoms of 
hyperthyroidism, atrial fibrillation, or unexplained weight loss and 
also women osteopenia (Levy et al., 1990). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter Two 
Materials and methods 
 
2.1. Statistical survey: 
Before samples collection a general statistical study was carried 
out of Sudanese subjects visited the SAEC laboratories during 1994-
1996. The study focused on the variation in sex type, age, subject's 
status, whether they were new cases or under treatment and their 
thyroid status.  
 
2.2. Subjects 
 This study involved 120 women, aged between 35-65 years, and 
attended the Radiation and Isotopes Center, Khartoum (RICK), Radio- 
immunoassay laboratory, during February, 2005 to August, 2006, 
suspected as cases of thyroid dysfunction. Subjects were divided into 
three equal groups: euthyroid as control, subclinical hypothyroid and 
subclinical hyperthyroid subjects. Subclinical hyperthyroidism 
describes conditions characterized by a low thyroid stimulating 
hormone (TSH) and normal levels of circulating thyroid hormones 
(thyroxine and triiodothyronine) (Helfland, 2004). Subclinical 
hypothyroidism is a condition in which there are small elevations in 
thyroid stimulating hormone, yet normal circulating levels of thyroid 
hormones (William and William, 2004) .In the present study subjects 
that considered as subclinical hypothyroid cases had serum TSH levels 
between (6.0-10 mIU/l) and euthyroid values for T3 and T4. While, 
  
subjects that considered as subclinical hyperthyroid had serum TSH 
levels between (0.1- 0.3 mIU/l) and euthyroid values for T3 and T4. 
 
2.3. Samples and sampling techniques 
Blood samples (5 ml) were collected form the cubital vein after 
overnight fasting. The blood samples were allowed to clot at room 
temperature and then centrifuged at 4000 r.p.m to obtain the serum. 
The clear serum was taken immediately for analysis or stored at -20 C ْ
for further use. 
 
2.4. Laboratory methods 
The levels of TSH, T4, and T3 were estimated by using 
Radioimmunoassay (RIA) technique, while commercial enzymatic 
methods were used for determination of total cholesterol, 
triglycerides, LDL-cholesterol, and HDL-cholesterol.  
2.4.1. Radioimmunoassay (RIA) 
(RIA) kits are all supplied by the Department of Isotopes, China 
Institute of Atomic Energy, 1994. Each Kit has specific code :     
IMK-437, IMK-438, IMK-432 for T4, T3, and TSH respectively. 
 
2.4.1.1. T4 kits 
These kits consisted of 6 vials of lyophilized standards for T4 to 
give different concentrations when reconstituted by 1 ml of distilled 
water. (0.0, 26, 52, 104, 208, 416 nmol/l) thyroxin.  
One vial of T4-I125 tracer and T4 antibodies coupled to magnetic 
particles, and one vial for quality control (QC) sample. 
  
2.4.1.2. T3 kit 
Included 6 vial of triiodothyronine, standard solution in 
different concentrations, (0.0, 0.5, 1.0, 2.0, 4.0, 8.0 nmol/l) 
triiodothyronine.       
One vial contains T3-I125 tracer, one vial Anti-T3 antibody, and one 
vial of (QC) sample. 
 
2.4.1.3. Thyroid stimulating hormone (TSH) kit 
Contains 7 vial standard solution of TSH with known 
concentration as follow:    A. 0.0 mIU/L   B. 0.23 mIU/L.  C. 1.0 
mIU/L.  D. 3.0 mIU/L.    E. 10.0 mIU/L.    F.20.0 mIU/L. G. 80.0 
mIU/L. 
One vial contain  anti-TSH antibodies coupled to magnetic 
particles,(solid phase separation system), one vial of tracer (labeled 
anti TSH with I125, one vial wash Buffer, 3 vial of QC samples A, B, C 
with different ranges. 
Equipments 
1. Adjustable micropipettes (10-200µl) with disposable tips. 
2. Polystyrene test tubes (disposable). 
3. Vortex mixer (single and multi-tubes). 
4. Multidose micropipette (Eppendorfe).25µl and 250 µl, 
magnetic base (separator). 
5. Water bath 
6. Incubator 
7. Centrifuge 
8. Gamma counter (connected with computer contains. 
International Atomic Energy Agency (IAEA) programme. 
  
Assay procedure 
2.4.1.4. T4 
Sufficient (polystyrene) test tubes were labeled in duplicates 
and arranged in assay rack, and then 25 µl were pipetted into each 
tube of the standards, quality control sample and patient's sample. And 
250 µl anti T4 antibody were added to each tube, and mixed well, to 
the STD and QC and samples250 µl of tracer were added. 
After well mixing the tubes were incubated at 37 Co for 45 
minutes, then the rack was placed in the magnetic base for 10 minutes, 
to separate the bound fraction free from the free fractions by decanting 
the supernatant. Lastly, each tube was counted in the gamma counter 
to evaluate the gamma emission per minutes, and binding percent was 
plotted vs. the concentration, to get standard calibration curve, and 
from the curve obtained the concentration of thyroxin in the patient's 
samples was evaluated. This method is bioassay method, 
(Radioimmunoassay), using radio active isotope of iodine. (I125) which 
is gamma emitter.  
2.4.1.5. T3 
Sufficient number of test tubes were labeled and in duplicate 
arranged in assay rack. 25 µl of standard solutions, QC samples and 
patients sample were added to each target tube. 250 µl of T3- I125 
tracer and 100 µl anti-T3 antibody were added to each tube and mixed. 
After mixing, the tubes are incubated at 37Co for one hour and then 
vortexed well and centrifuged to separate bound fraction,(liquid phase 
separation system) the supernatant was decanted and then each tube 
was placed in gamma counter. The principle of the assay is the same 
as that for T4. 
  
2.4.1.6. TSH 
Sufficient test tubes were labeled and arranged in assay rack in 
duplicates. 100 µl of STD and QC and samples were pipetted in target 
tubes and 25 µl tracer (anti TSH labeled by I125) were added to each 
tube and vortexed gently, and then incubated at 37Co in the incubator 
for one hour. 250 µl of anti TSH (antibody coupled to magnetic 
particles) were added to each tube and mixed well and incubated at 
25Co for one hour. Then the racks were placed in the magnetic 
separator for 10 minutes and the supernatant was separated by 
decantation.    
Washing step 
  In this step first the concentrated wash buffer was diluted by 
adding water (1:9), and then 500 µl of the diluent was added to each 
tube and then vortexed well and then placed again in the magnetic 
base and allowed to stand for 10 minutes. Then the supernatant was 
decanted and drained thoroughly on adsorbent paper. The wash step 
was repeated again. All the tubes were counted in the gamma counter, 
to evaluate the concentration of TSH in the patient sample. 
The quantitative analysis of TSH is achieved by the above 
method, which is immunoradiometric method. It is non- competitive 
method in which the radio- active compound (tracer) is TSH antibody. 
There are two antibodies which react with the TSH in the analyte to 
get a sandwich complex. 
Calculation of results 
The results in these two methods are obtained by using 
computerized method in which a soft ware provided from 
International Atomic Energy Agency (IAEA) was used. 
  
     The count per minute of each tube was counted in the Gamma 
counter, to get the emission all tubes in one minute including the 
patients samples, the standard curve was plotted, the concentration of 
T3, T4, TSH standards in the X axis Vs. the bound percentage (the 
count of each standard over the total count B/T%) in the y axis. 
 
 
 
B0/T % =   B0 (cpm) - NSB (cpm)                    Χ 100     . 
                                 T (cpm) - Background count (cpm) 
 
              % Bound = B-NSB              Χ 100 
                                  B0- NSB 
Where: 
• NSB: Non specific binding counts. 
• B0: Average zero standard count. 
• B: Average standard (or sample) counts. 
 
Then concentration of each sample was calculated from the 
standard curve (normal interpolation). 
 
2.4.2. Estimation of serum lipids 
Equipments and reagents 
1. Polystyrene test tubes (disposable). 
2. Vortex mixer (single and multi-tubes). 
3. Multidose micropipette. (Eppendorfe).25µl and 250 µl, 
4. Water bath. 
5. Spectrophotometer (Biosystem 305- BTS), with 500 nm filter       
    (490-510). 
  
• All kits and reagent were supplied by (Biosystems) company, for 
reagents and instruments. Methods and procedures are applied according 
to the instruction described in the kits manuals. Each Kit has specific 
code: 11505 (1 X 200 ml), 11648, 11579, and 11528 for Cholesterol, 
HDL-C, LDL-C, and TG respectively. 
 
2.4.2.2. Estimation of total cholesterol 
Principle of the method 
 In the presence of Cholesterol esterase, the cholesterol esters in the 
sample are hydrolyzed to cholesterol and free fatty acids. The cholesterol 
produced is oxidized by Cholesterol oxidase to cholestenone and 
hydrogen peroxide. Hydrogen peroxide is detected by a chromogenic 
oxygen acceptor, phenol- ampyrone, in the presence of Peroxidase. The 
red quinine formed is proportional to the amount of cholesterol present in 
the sample. (Deeg, and Ziegenhorn 1983). 
Cholesterol ester + H2O                     CHE          Cholesterol + fatty acid 
Cholesterol + 1/2 O2 +H2                   CHOD        Cholesterol + H2O2 
2H2O2 + Aminoantipyrine + Phenol      POD         Quinoniemine +4H2O 
 
Contents and composition of reagents 
1- Reagent-1 (Buffer):  PIPES PH 6.9 90 mmol/l, phonol 26 mmol/l 
  
2- Reagent-2 (Enzymes): Cholesterol esterase (CHE) 300 U/ml, 
Cholesterol oxidase (CHOD) 300 U/L, Peroxidase (POD) 1250 
U/ml,   4-aminoantipyrine (4-AP) 0.4 mmol/l, pH 7.0. 
3- Cholesterol standard 200 mg/dl. 
Procedure 
1- The working reagent was prepared by dissolving one vial of 
Reagent-2 enzymes in one bottle of reagent-1 Buffer.   
2- The working reagent was brought to room temperature. 
3- Into labeled test tubes the following were pipetted: 
 Blank Standard (ST) Sample (S) 
Cholesterol standard  10 µl   
Sample - - 10 µl 
Working reagent 1.0ml 1.0ml. 1.0ml 
  
4- The tubes were incubated for 10 minutes at room temperature (16-25 
C)ْ. 
5- The absorbance (A) of the standard and the samples were measured at 
500 nm against the blank. 
Calculations 
Cholesterol (mg/dl)  =  AS  X 200 
        AST     
  
2.4.2.3. Estimation of high- density lipoprotein Cholesterol(HDL-C) 
Principle of the method 
 Very low-density lipoprotein (VLDL) and low density lipoprotein 
(LDL) in the sample are precipitated with phosphotungsate and 
magnesium ions. The supernatant contains high-density lipoproteins 
(HDL). The HDL-cholesterol is then spectrophotometerically measured 
by means of the coupled reactions as described in total cholesterol in 
page 32. 
Contents and composition of reagents 
1- Reagent B: 50 ml, phosphotungsate 0.4 mmol/L, magnesium 
chloride 20 m mol/L 
2- HDL-cholesterol standard 3 ml cholesterol 40 mg/dL 
3- Cholesterol Kit (Biosystmcode. 11505, 11506, 11539) 
Procedure 
Precipitation 
1- Into labeled test tubes the following were pipetted: 
Sample 0.2 ml 
Reagent B 0.5 ml 
2- The tubes were let to stand for 10 minutes at room temperature. 
3- Centrifuged at minimum of 4000 r.p.m for 10 minutes. 
4- The supernatant was collected carefully. 
Colorimetry  
  
1- The cholesterol reagent brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
3- The tubes were incubated for 10 minutes at 37 C.ْ 
4- The absorbance (A) of the sample and the standard were measured 
at 500 nm against the blank. 
Calculations 
HDL-cholesterol (mg/dl) = AS   X 3.5 X 40      
            ASt 
 
2.4.2.4. Estimation of low- density lipoprotein cholesterol (LDL-C) 
Principle of the method 
 Low- density lipoprotein (LDL) in the sample is precipitated with 
ploy vinyl sulphate. Their concentration is calculated from the difference 
between the serum total cholesterol in the supernatant after centrifugation. 
The cholesterol is spectrophotometerically measured by means of the 
coupled reactions as described in total cholesterol in page 32. 
 Blank Standard (ST) Sample (S) 
Distilled water 100 µl -  - 
HDL-cholesterol 
standard 
- 100 µl - 
Sample supernatan - - 100 µl 
Cholesterol standar 1.0 ml 1.0 ml. 1.0 ml 
  
Contents and composition of reagents 
1- Reagent B: 10 ml polyvinyl sulphate 3 g/L, polyethylene glycol 3 g/L. 
2- Cholesterol kit (Biosystem code 11505, 11506, 11539). 
 
Procedure 
Precipitation 
1- Into labeled test tubes the following were pipetted: 
Sample 0.2 ml 
Reagent B 0.1 ml 
2- The tubes were let to stand for 10 minutes at room temperature. 
3- Centrifuged at minimum of 4000 r.p.m for 10 minutes. 
4- The supernatant was collected carefully. 
Colorimetry  
1- The cholesterol reagent was brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
 Blank Standard (ST) Sample (S) 
Distilled water 20 µl -  - 
Cholesterol standard - 20 µl - 
Sample supernatant - - 20 µl 
Cholesterol reagent 1.0 ml 1.0 ml 1.0 ml 
  
3- The tubes were mixed and incubated at room temperature for 30 
minutes. 
4- The absorbance (A) of the sample and the standard were measured at 
500 nm against the blank. 
Calculations 
 The dilution factor of the sample in the precipitation is 1.5 and the 
concentration of the standard is 200 mg/dL according to the following 
formula is; 
cholesterol in the supernatant (mg/dl) =  As  X 1.5 X 200      
  Ast 
LDL- cholesterol = Total- cholesterol     Cholesterol in the supernatant. 
 
2.4.2.5. Estimation of triglycerides 
Principle of the method 
Triglycerides in the sample originate, by means of the coupled 
reactions described below, a colored complex that can be measured by 
spectrophotometry (Fossati and Prencipe, 1982). 
Triglycerides + H2O            lipase                 Glycerol + Fatty acids 
Glycerol + 3ATP       glycerol kinase            Glycerol-3-p + 3ADP   
Glycrtol-3-p + O2       G3p-oxidase        Dihydroxyacetone-p + H2O2  
2H2O2 + 4-Aminoantipyrine + 4-cholesterol peroxidase Quinoneimine + 4H2O 
  
Contents and composition of reagents 
 
1- Reagent A.  PIPES 45mmol/L, magnesium chloride 5mmol/L, 4-
chlorophenol 6mmol/L, lipase > 100 U/ml, glycerol kinase > 1.5 
U/ml, glycerol-3-phosphate oxidase > 4 U/ml, peroxidase > 0.8 
U/ml, 4-aminoantipyrine 0.75mmol/L, ATP 0.9mmol/L, PH 7.5. 
2- Triglycerides standard. Glycerol equivalent to 200 mg/dl 
triolein. 
Procedure 
1- The Reagent was brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
 
3- The tubes were incubated for 15 minutes at room temperature. 
4- The absorbance (A) of the standard and sample was measured         
 at 500 nm against the blank. 
Calculations  
triglycerides (mg/dL) = AS  X  200    
   ASt 
2.5. Statistical analysis 
Statistical analysis was done using the Statistical Package for Social 
Sciences (SPSS 10.1). Different statistical methods were used as 
appropriate. Mean + SD was determined for quantitative data and 
frequency for categorical variables. 
   Blank Standard (ST) Sample (S) 
Triglycerides standard - 10mL - 
Sample - - 10mL 
Reagent 1.0mL 1.0mL 1.0mL 
  
Chapter Three 
Results 
 
3.1 Data from statistical survey 
Data collected form the survey study was analyzed using statistical 
package for social sciences (spss 10.1). The total number of subjects 
visited RIA Lab, SAEC during (1994-1996) were about 4268 subjects. 
3644 subjects visited the RIA Lab for the first time, while a number of 624 
were reported as subjects under treatment (Appendices, I and II). Males 
represent 538 of the whole subjects, 85.13% of them were new cases and 
14.87% were under treatment (Appendix, III). In contrast, 3730 out of the 
total number were females, 85.42% of them were new cases while 14.58% 
under treatment (Appendix, IV). The mean age among both males and 
females was found to be similar (32.0 + 17.35, 30.8 + 11.84) respectively 
(Appendix, V). 
(Appendix, VI) shows the incidence of hypothyroidism and 
hyperthyroidism among subjects. 426 of the total number of males were 
considered as euthyroid with percentage of 79.18%, while 69 males were 
found to have hyperthyroidism with percentage of 12.82% and 43 subjects 
with a percentage of 8.0% were found to have hypothyroidism, (Appendix, 
VII). Among females, 3139 were considered as euthyroid with percentage 
of 84.15%, while 414 females were found to have hyperthyroidism with 
percentage of 11.10% and 220 subjects with a percentage of 5.15% were 
found to have hypothyroidism, (Appendix, VIII). 
 
   
Table (1): Normal ranges of some serum metabolites. 
 
 
   No                Metabolite Normal range References 
  1 Serum total thyroxine 50-150 nmole/l Edward (1980) 
   2 Serum total triiodothyronine 0.8-3.0  nmole/l Edward (1980) 
   3 Serum total thyroid stimulation hormone 0.4-4.0 mIU/ml Edward (1980) 
   4 Serum total cholesterol Desirable up to 200mg/dl 
Suspect >220mg/dl 
High risk >240 mg/dl 
 
Richmond (1973) 
   5 Serum high density lipoprotein cholesterol Female < 65 mg/dl Assmam (1979) 
   6 Serum low density lipoprotein cholesterol <150  mg/dl Friedewald et al. (1972) 
   7 Serum triglycerides 35-160 mg/dl Young and  Pestoner (1975)
  
3.2 Thyroid hormones and TSH in the study groups 
In the present study, one hundred and twenty women were selected. 
Forty women fit the criteria for subclinical hypothyroidism, equal number 
considered as subclinical hyperthyroidism cases, and the left 40 were 
euthyroid and selected as controls. The normal range of all parameters 
measured is presented in table (1). 
Serum concentration of thyroxin (T4), triiodothyronine (T3) and 
thyroid stimulating hormone (TSH) in subjects studied are shown in tables 
(2) and (3).  
The mean levels of T4 in serum of the control group, subclinical 
hypothyroid and subclinical hyperthyroid subjects were found to be within 
the same range (94.28+ 9.97, 89.70+ 11.39, 103.30+ 15.23) nmole/l 
respectively, (Fig. 1). 
The same findings are reported for T3 levels (1.96+ 0.470, 1.95+ 
0.45, and 2.19+ 0.38) nmole/l respectively, (Fig. 2). 
The normal mean level of TSH, when determined in this study, was 
found to be (1.60+ 0.54 mIU/ml). Subclinical hypothyroid cases, showed 
significantly higher levels (P < 0.001) of (9.55+ 2.69 mIU/ml) compared 
to controls. While there was a significantly lower level (P < 00.001) 
among subjects with subclinical hyperthyroidism subjects, of mean TSH 
equals (0.18+ .08 mIU/ml) compared to the control, (Fig. 3). 
3.3 Serum total cholesterol, triglycerides, LDL-C, and HDL-C 
Serum lipid values for the all three study groups, showed that persons 
with subclinical hypothyroidism and subclinical hyperthyroidism were  
 
   
Table (2): Serum concentrations of triiodothyronine (T3), Thyroxine (T4), and thyroid stimulating  
hormone (TSH) in subclinical hypothyroid and euthyroid subjects. Mean + SD, N = 40 
 
                                parameters 
subjects                                
T3 nmole/l T4 nmole/l TSH mIU/ml 
Euthyroid subjects 01.96 a + 00.47 94.28 a + 09.97 01.60 a + 00.54 
Subclinical Hypothyroid subjects 01.95 a + 00.45 89.70 a + 11.39     09.55 b + 02.69 
 
• Means within the same column having different letters were significantly different, at (p < 0.001). 
• N= Number of replicates. 
 
 
 
 
 
 
 
 
 
 
   
Table (3): Serum concentrations of triiodothyronine (T3), Thyroxine (T4), and thyroid stimulating  
hormone (TSH) in subclinical hyperthyroid and euthyroid subjects. Mean + SD, N = 40 
 
                                parameters  
subjects                                
T3 nmole/l T4 nmole/l TSH mIU/ml 
Euthyroid subjects 01.96 a + 00.47 94.28 a + 09.97 01.60 a + 00.54 
Subclinical Hyperthyroid subjects 02.19 a + 00.38 103.30 a + 15.23 00.18 b + 00.08 
 
• Means within the same column having different letters were significantly different, at (p < 0.001). 
• N= Number of replicates. 
 
 
 
 
 
 
 
 
 
  
Fig ( 1): Mean T4 among different study groups
94.27
89.7
103.3
80
85
90
95
100
105
Euthyroid Subhypo Subhyper
Study Group
M
ea
n 
T4
 
 
  
Fig (2 ): Mean T3 among different study groups
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Fig ( 3): Mean TSH among study groups
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more likely to have higher levels in their average cholesterol (Ch), 
triglycerides (TG) levels, as well as low density lipoprotein-cholesterol 
(LDL-C) compared to euthyroid subjects. The mean concentrations of total 
cholesterol, TG, LDL-C, and HDL-C are presented in tables (4) and (5). 
Subjects with subclinical hypothyroidism showed significantly 
higher levels of cholesterol (P < 0.001) compared to euthyroid subjects. 
The mean concentrations of cholesterol were (172.68 + 31.0, 237.50 + 
40.5) mg/dl in controls and subclinical hypothyroid subjects respectively, 
(Fig. 4). 
The same findings were true for TG. In subclinical hypothyroid 
subjects the mean level was (168.53 + 35.6) mg/dl and this is significantly 
higher (P < 0.01) than the euthyroid level which was only (129.75 + 31.8) 
mg/dl, (Fig. 5). 
When LDL-C levels were considered, again there was statistically 
significant relationship between subclinical hypothyroid cases and the 
controls (P < 0.03). The mean of the serum concentrations were (166.25 + 
41.3 and 123.95 + 32.6) mg/dl respectively, (Fig. 6). There was no 
significant difference reported in the levels of HDL-C (P < 0.5). The mean 
of the serum levels among the controls and the subhyopthyroid subjects 
were (52.05 + 11.5, and 52.20 + 9.6) mg/dl respectively, (Fig. 7). 
When serum lipid values for the subclinical hyperthyroid subjects 
were compared with values of the control group, no statistically significant 
difference was found. The mean levels of cholesterol in subhyperthyroid 
subjects and the controls were (172.15 + 29.7 and 172.68 + 31.0) mg/dl 
respectively, (Fig. 4). For LDL-C and HDL-C, the results were (123.95 + 
32.6, 115.28 + 29.4) mg/dl and (52.05 + 11.5, 48.57 + 10.9) mg/dl for the 
controls and the subhyperthyroid subjects respectively, (Figs. 6, 7). The 
  
only statistically significant difference, (P < 0.01), was found for the TG 
levels when comparison was made between the subhyperthyroid and 
euthyroid subjects. The mean levels were (165.00 + 27.3 and 129.75 + 
31.8) mg/dl respectively, (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Table (4): Serum concentrations of triglycerides (TG), total cholesterol (Ch), low density 
lipoproteins cholesterol (LDL-C), and high density lipoproteins cholesterol, (HDL-C) in subclinical 
hypothyroid and euthyroid subjects. Mean + SD, N = 40 
 
                                parameters
subjects                                
TG mg/dl Ch mg/dl LDL-C mg/dl HDL-C mg/dl
Euthyroid subjects 129.75 a + 31.8 172.68 a + 31.0 123.95 a + 32.6 52.05 a + 11.5
Subclinical Hypothyroid subjects 168.53 b + 35.6 237.50 b + 40.5 166.25 b + 41.3 52.20 a + 9.6 
 
• Means within the same column having different letters were significantly different, at (p < 0.05). 
• N= Number of replicates. 
 
 
 
 
 
 
 
 
 
   
Table (4): Serum concentrations of triglycerides (TG), total cholesterol (Ch), low density 
lipoproteins cholesterol (LDL-C), and high density lipoproteins cholesterol, (HDL-C) in subclinical 
hyperthyroid and euthyroid subjects. Mean + SD, N = 40 
 
                       parameters 
 subjects                                
TG mg/dl Ch mg/dl LDL-C mg/dl HDL-C mg/dl 
Euthyroid subjects 129.75 a + 31.8 172.68 a + 31.0 123.95 a + 32.6 52.05 a + 11.5 
Subclinical Hyperthyroid subjects 165.00 b + 27.3 172.15 a + 29.7 115.28a + 29.4 48.57 a + 10.9 
 
• Means within the same column having different letters were significantly different, at (p < 0.05). 
• N= Number of replicates. 
 
 
 
 
 
 
 
  
Fig ( 4) : Mean Cholesterol among different study 
groups
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Fig ( 5): Mean TG among different study groups
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Fig ( 6) : Mean LDL-C among different study groups
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Fig (7 ) : Mean HDL-C among different study groups
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Chapter Four 
Discussion 
 
Recently, several reports have shown that lipid abnormalities are 
encountered in patients with subclinical thyroid dysfunction; which may 
be attributed to impaired thyroid function (Hak et al., 2002, William and 
William, 2004). 
4.1 Subclinical hypothyroidism 
 In this study subjects that considered as subclinical hypothyroid 
cases are obviously have elevated TSH levels and euthyroid values for 
T3 and T4 which match the definition of subclinical   hypothyroidism. 
These findings are explained by Adlen, (1998), who assumed that the 
elevation of TSH levels reflects the sensitivity of the hypothalamic-
pituitary axis to small decreases in circulating thyroid hormone; as the 
thyroid gland fails, the TSH level may rise above the upper limit of 
normal when the free T4 level has fallen only slightly and is still within 
the normal range. 
 The effect of subclinical hypothyroidism on serum lipid levels and 
cardiovascular disease remain surrounded by controversy. In the present 
study hypercholesterolemia was a common criterion among subclinical 
hypothyroid women. It is generally well known and repeatedly published 
that patients with subclinical hypothyroidism show increased levels of 
cholesterol (William and William, 2004). This is believed to be resulted 
from impaired metabolism due to a decreased thyroid function. The same 
results are found to be true for LDL-C and TG among the subclinical 
  
hypothyroid subjects. However, the HDL-C levels were found to be 
within the normal range.  
Recent cross-sectional study of 279 women older than 65 found 
that women who had a serum TSH greater than 5.5 mU/l had 13% higher 
LDL-cholesterol and 13% lower HDL-cholesterol than those with a 
normal serum TSH (0.1-5.5 mU/l), (Bauer et al, 1998). Also the Colorado 
study and others noted significantly elevated LDL cholesterol in subjects 
with subclinical hypothyroidism (Canaris et al., 2000, Kahaly, 2000). 
Some, cross-sectional studies have demonstrated that serum levels of 
total cholesterol and LDL-cholesterol are higher in patients with 
subclinical hypothyroidism than euthyroid controls as reported by Elder 
et al, (1990). 
 In some studies the relation between TSH and total cholesterol or 
LDL-C is inconsistent. In a survey carried out in (1977), the Wickham 
study, no reported relations were found between subclinical 
hypothyroidism and hyperlipidemia (Tunbridge et al., 1977). Also in the 
Rotterdam survey, a population- based cross sectional study, lipid levels 
were significantly lower among euthyroid women. They claim that, this 
might be an artifact of higher use of diet or other lipid-lowering therapy 
(Hak et al., 2002). Other several studies showed a significant reduction of 
euthyroid state with thyroxine substitutive treatment as reported by 
Langer et al, (2003).  
The New Mexico Elder Healthy Survey, which was a fair quality 
study of randomly selected Medicare recipients, no differences founds in 
HDL-C and LDL-C levels between euthyroid subjects and those who had 
serum TSH greater than 10 mU/l (Lindeman et al., 1999). 
  
Another large field surveys carried by Langer et al, (2003), 
focused on the elvaluation of thyroid status of Slovak rural population 
demonstrated that there was no difference in the level of TG and 
cholesterol. They assumed that this interrelation resulted from very high 
cholesterol intake due to inappropriate general nutritional status of rural 
population resulting from the consumption of unhealthy foods.  
 Moreover, Williams and Williams , (2004), in a population-based 
study, concluded that subclinical hypothyroidism does not appear to be 
associated with abnormalities in serum cholesterol or TG levels when 
adjusted for confounding variables. 
4.2 Subclinical hyperthyroidism 
As mentioned before, the literature on assessment and treatment of 
patients with subclinical hyperthyroidism is markedly less extensive. The 
precise pathophysiology, natural history, prevalence, risks and long-term 
outcome of subclinical hyperthyroidism are unknown. Diane and 
Kenneth, (2002) reported that in the United States, subclinical 
hyperthyroidism became an entity that is increasingly recognized, 
probably of the aging of the Untied States population and the 
development of assays with enhanced TSH sensitivity. 
 In the present study subjects with subclinical hyperthyroidism were 
found to have normal serum T3 and T4 with TSH levels suppressed 
below the normal range. Diane and Kenneth, (2002), reported that, the 
decreased levels of subclinical hyperthyroidism is due to the sensitivity 
of the pituitary gland to respond to minor elevations in serum or tissue T4 
and T3. Although the levels of T3 and T4 remain within the normal 
  
range, minimal increases in these thyronines are sufficient to decrease the 
serum TSH (Diane and Kenneth, 2002). 
 The present study has detected no significant differences in total 
serum cholesterol levels between subjects with subclinical 
hyperthyroidism and euthyroid subjects. Also there was no significant 
effects found regarding the HDL-C or LDL-C levels. These results to 
some extent are not surprising, since many studies, concerning patients 
with overt hyperthyroidism, reported that hyperthyroidism is associated 
with decreased or normal concentrations of total cholesterol and the other 
serum lipoproteins and lipids (Prale et al., 1992, Arem et al., 1996, 
Duntas, and Leonidas, 2002). Moreover, Hansson, (1983) studied the 
effect of experimental hyperthyroidism on plasma lipoproteins and stated 
that, the decreased LDL-cholesterol concentrations in hyperthyroid 
patients may be due to a mechanism include both an increased number of 
LDL-receptors and enhanced transfer of cholesterol and phospholipids to 
the LDL sub-fraction with subsequent rapid uptake in the liver via 
hepatic lipase. Another study carried by Caparevic, et al (2000), included 
55 elderly patients with subclinical hyperthyroidism, concluded that 
patients with subclinical hyperthyroidism tend to have low serum total 
cholesterol, LDL-cholesterol and HDL-cholesterol levels. Also they 
found a significant increase of serum cholesterol, LDL-cholesterol and 
HDL-cholesterol levels after treatment.  
In the present study, the triglycerides values among subjects with 
subclinical hyperthyroidism and the controls are found to be different. 
The subclinical hyperthyroid subjects showed higher values compared to 
the controls. These findings were similar to those obtained by Davidson 
et al, (1988), who observed that concentrations of triglycerides were 
  
higher in patients with subclinical hyperthyroidism compared to 
euthyroid subjects. They found this observation is not surprising as 
hyperthyroidism is known to exert widespread effect on hepatic 
triglycerides assembly and secretion. On the other hand, it was 
demonstrated by some authors that triglycerides metabolism is disturbed 
due to thyroid dysfunction but to smaller extent than that of plasma 
cholesterol, (Muller, 1984 and Barbagallo, 1995). 
Relaying on these findings above, and the fact that thyroid 
hormones could increase lipolysis, it is fairly expected that the levels of 
serum lipids in patients with subclinical hyperthyroidism are decreased or 
at the normal range. 
In this study, subjects with subclinical hyperthyroidism, to some 
extent, are found to be having normal serum lipids, suggesting that there 
might not be relationship between subclinical hyperthyroidism and lipids 
abnormalities.  
Worthy to be noted, most of researchers and authors focused on 
other implications that related to subclinical hyperthyroidism. These 
include atrial fibrillation, osteoporosis, and cardiovascular diseases.  
 
 
 
 
 
 
  
Conclusions 
 
The present study is carried out to estimate the changes of serum 
lipids related to subclinical thyroid dysfunction in Sudanese females' 
subjects, compared to euthyroid individuals. 
Subjects with subclinical hypothyroidism showed higher serum 
levels of cholesterol, LDL, and TG which are significantly different from 
the euthyroid subjects. These findings are found to be in agreement with 
studies conducted abroad among different populations in the United 
States and Europe.  
Unfortunately, records on the levels of the thyroid hormones in 
euthyroid subjects and cases of thyroid dysfunctions are lacking in 
Sudan. Also there is no any kind of studies that focus on changes in the 
plasma lipids profile associated with subclinical thyroid dysfunctions and 
how this is affected by other factors such as age and sex. 
Recommendations 
Further multi-center randomized and population based studies are 
needed in our community to study the relation between subclinical 
thyroid dysfunctions and cardiovascular disease and other risk factors. 
Large-scale controlled intervention and outcome trials are also needed to 
assess the potential benefit of L–thyroxine treatment and anti thyroid 
medications in subjects with subclinical hypo and hyper thyroidism, so 
further recommendation regarding screening for the thyroid disease in the 
community will influenced by the results of these studies. 
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Appendix (I) 
 
The Percentage of Sudanese subjects visited RIA Lab, SAEC 
during (1994-1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Under treatment New cases Sex 
No % No % 
Total 
Male 80 14.87 458 85.13 538 
Female 544 14.58 3186 85.42 3730 
Total 624 14.71 3644 85.29 4268 
  
Appendix (II)
 The percentage of Sudanese subjects visited RIA 
Lab, SAEC during (1994-1996).
538
13%
3730
87%
Males Females
 
  
Appendix (III)
 The percentage of Sudanese males visited RIA 
Lab, SAEC during (1994-1996).
80
15%
458
85%
Undertreatment New Cases
 
  
Appendix (IV)
The percentage of Sudanese females visited RIA 
Lab, SAEC during (1994-1996).
544
15%
3186
85%
Undertreatment New Cases
 
  
Appendix (V)
Means ages among patients’under study
32
30.8
30.2
30.4
30.6
30.8
31
31.2
31.4
31.6
31.8
32
32.2
Males Females
Sex
A
ge
 
 
  
 
 
 
Appendix (VI) 
 
    The incidence of hypothyroidism and hypothyroidism among      
    subjects visited RIA Lab, SAEC during (1994-1996). 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Hypothyroidism HyperthyroidismSex 
No % No % No % 
Male 426 79.18% 43 8.00% 69 12.82% 
Female 3139 84.15% 177 4.75% 414 11.10% 
Both 3565 83.53% 220 5.15% 483 11.32% 
  
Appendix (VII)
The incidence of hypothyroidism and 
hypothyroidism among males visited RIA Lab, 
SAEC during (1994-1996).
426
79%
43
8%
69
13%
Normal Hypo Hyper
 
  
Appendix (VIII)
The incidence of hypothyroidism and       
hypothyroidism among females visited RIA Lab, 
SAEC during (1994-1996).
3139
89%
177
5%
220
6%
Normal Hypo Hyper
 
  
 
